Last reviewed · How we verify

Active Ankylosing Spondylitis — Treatment Landscape & Competitive Intelligence

Active Ankylosing Spondylitis (disease) competitive landscape: 3 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

3 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Active Ankylosing Spondylitis, deduplicated by molecule. See the full disease page for line-of-therapy detail.

DrugGenericSponsorClassTargetLine of therapyFirst approval
Induction- PF-06480605 450 mg SC Q4W induction-pf-06480605-450-mg-sc-q4w Pfizer small molecule IL-17 receptor
tumor necrosis factor inhibitors (TNFi) tumor-necrosis-factor-inhibitors-tnfi Pfizer biologic tumor necrosis factor
TNF Inhibitor tnf-inhibitor Pfizer Monoclonal Antibody TNF-alpha

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

  1. Pfizer · 3 drugs in Active Ankylosing Spondylitis

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Active Ankylosing Spondylitis:

Cite this brief

Drug Landscape (2026). Active Ankylosing Spondylitis — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/active-ankylosing-spondylitis. Accessed 2026-06-10.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing